Could a common diabetes drug shrink fatty livers in obese teens?
NCT ID NCT06355310
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether empagliflozin (Jardiance), a drug used for diabetes, can reduce liver fat in teenagers with obesity and non-alcoholic fatty liver disease (NAFLD). Forty participants aged 16 to under 21 will receive either the drug or a placebo for 26 weeks. The main goal is to see if liver fat decreases, along with other health markers like weight and liver enzymes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (Jardiance)
What this could lead to
If it works, this could point toward a new treatment option for teenagers with fatty liver disease, potentially reducing liver fat and improving metabolic health.
What could go wrong
This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug is already approved for diabetes, but its safety and effectiveness for this specific condition in teens are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann & Robert H Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact